Hopp til innhold

Selected items added to basket

Go to basket


Middle East Respiratory Syndrome (MERS-CoV)


Illustrasjonsfoto dromedarer
Illustrasjonsfoto: Colourbox.com

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first identified in 2012. The virus can cause acute respiratory infections. Dromedary camels are suspected to be the most likely source of infection. To date, MERS has not been detected in Norway.

Have you found an error?


The MERS virus was first detected in September 2012 in a sample from a deceased patient in Saudi Arabia. Samples were then taken from a group of healthcare personnel in Jordan who became ill and the virus was detected in two who had died. In September 2012, the virus was detected in a man who was transferred from Qatar to the UK for intensive care. Since then, the virus has been detected in several countries in the Middle East. In some cases, infected individuals have travelled and further infected health institutions.

Over a thousand cases have since been confirmed, with many cases reported in spring. A possible explanation for the variation in occurrence of MERS cases in humans may be seasonal variations in virus prevalence in the population of dromedary camels although other factors may also play a role. 

Most cases have been detected in Saudi Arabia. Some have been detected in Europe, Africa, Asia and America. Only a few cases of infection to third parties in countries outside the Middle East have been reported. Many of the cases have arisen in outbreaks in hospitals. 

About MERS-CoV and transmission route

The coronavirus family includes many different viruses that usually cause respiratory infection. Many coronaviruses only cause common colds, but some may cause serious illness and sometimes death. Until 2012, the virus that causes MERS was a previously unidentified coronavirus. 

Coronavirus is also found in animals. Studies performed early in the MERS outbreak showed that parts of the MERS virus resemble a virus found in bats. Subsequently, MERS-CoV has been detected in dromedary camels, and studies show that large parts of the dromedary camel population have been in contact with the virus. The virus has not been detected in other domestic animals. 

Disease and symptoms

The MERS virus has been detected in both critically ill patients and those with less severe symptoms, but so far the majority have become seriously ill. Secondary cases (people infected by other people) often get milder clinical signs compared to the primary cases. The World Health Organization (WHO) and the European Centre for Disease Control (ECDC) issue regular information about the disease. 

Most patients had symptoms such as fever and cough followed by severe pneumonia. Acute respiratory distress syndrome (ARDS) and multi-organ failure, renal failure, disseminated intravascular coagulation (DIC) and pericarditis (inflammation of the pericardium) have been seen among the critically ill. Some patients had diarrhoea and one patient who was on immunosuppressive treatment only had gastrointestinal symptoms. Some patients have been diagnosed with co-infection with influenza A, herpes simplex I or pneumococci. 

The majority of those infected had chronic diseases and most of them were men, with an average age of about 50 years.  

Transmission route

There are still several aspects concerning the source of infection and transmission mode that are unknown. Studies indicate that MERS is a zoonosis which is a disease transmitted from animals to humans. Humans probably get infected by the virus through direct and indirect contact with dromedary camels.

It has been seen that the virus to a certain degree can be transmitted from person to person. It is believed that coughing / droplets are the main route of infection between people, but other transmission routes cannot be excluded. Sustained virus transmission among humans has not been demonstrated. Contact tracing around MERS cases that have travelled by plane to countries outside the Middle East, has so far not resulted in detection of virus transmission to other passengers.

Incubation time

Studies show that the preliminary incubation period (time from infection to when symptoms occur) is somewhere between 2-14 days, although most people probably develop symptoms after 3-4 days.

Diagnosis and treatment

The virus can be detected in airway samples, particularly the lower airways. The Norwegian Institute of Public Health’s laboratory has diagnostic methods to detect the virus.

There is no specific treatment or vaccine for MERS. The disease is treated symptomatically, e.g. with mechanical ventilation when required. Prompt medical attention is important.

Prevention of MERS

There is no vaccine or preventive medicine against the disease. Good hand-hygiene is an important preventive measure which applies for all infections, including MERS. Avoid close contact with people with acute respiratory disease when travelling in the Middle East. Travellers are also recommended to avoid contact with animals, particularly dromedary camels in the Middle East. Avoid drinking camel milk and camel urine and do not eat meat that has not been thoroughly heat-treated. The term Middle East refers to countries around the eastern Mediterranean and eastward, in addition to the countries of the Persian Gulf. Turkey is not considered to be part of the Middle East.

Studies into the use of face masks have not been able to document a positive health effect of healthy people wearing them outside healthcare settings. Incorrect use is common, and people who use face masks touch their face more frequently, which may increase the risk of infection. Therefore, we do not recommend that healthy people use face masks. We have issued different recommendations for healthcare professionals and others who treat patients. People who have been infected may also wear face masks to avoid spreading the virus. 

When should medical help be sought?

If you have been in the Middle East during the past 14 days and have symptoms of pneumonia, consult your physician. Patients hospitalised with symptoms of severe respiratory disease and who have been in the Middle East during the past 14 days should be tested for MERS-CoV and other possible infections. Physicians should be aware that patients on immunosuppressive therapy may display different symptoms than respiratory symptoms following MERS infection.

Travel advice

The travel advice for MERS applies particularly when travelling to Middle Eastern countries.

Most cases of MERS have originated in Saudi Arabia. A few have been diagnosed in Europe, either because they were transferred to a European country for intensive care, or because they became ill after staying in the Arabian Peninsula. In some countries, it has also been transmitted to close contacts, including other patients and staff in hospitals. 

The disease has been confirmed in patients who have been travelling to or living in the following countries in the Middle East:

  • Saudi Arabia
  • The United Arab Emirates
  • Qatar
  • Jordan
  • Oman
  • Kuwait
  • Yemen
  • Lebanon
  • Iran
  • Egypt

The infection has been confirmed in people in France, England, Germany, Italy, Greece, the Netherlands, Austria, Tunisia, Algeria, Malaysia, the Philippines, the USA and Turkey who have returned from the Middle East.

No travel restrictions

Advice about travel restrictions to some of the countries where MERS-CoV is reported has not been given. The World Health Organization has not advised against travel to the region.

Advice to health professionals

  • Healthcare professionals should be aware that Norwegian passengers may be infected with the virus if they have stayed in the Middle East and have developed signs of pneumonia of unknown cause or acute respiratory distress syndrome (ARDS) during the last 10 days after their visit. The Middle East refers to the countries around the eastern part of the Mediterranean and further east, in addition to the countries of the Persian Gulf. Turkey is not considered as part of the Middle East.
  • In suspected cases, the patient should be hospitalised. Airborne precautions should be implemented until the viral diagnosis is disproved.
  • Healthcare professionals who treat confirmed cases of this disease, and people who have been in contact with the patients should be followed up and monitored for possible symptoms over a period of two weeks.

Notification of suspected cases

  • Healthcare professionals who suspect or detect a case should immediately notify the local Municipal Health Officer, according to the regulations for notification of and response to serious incidents with significance for international public health (IHR Regulations).
  • If it is not possible to notify the Municipal Health Officer, the Norwegian Institute of Public Health should be notified directly.
  • The Municipal Health Officer will notify the County Governor and the Norwegian Institute of Public Health.
  • The Norwegian Institute of Public Health can be notified by ringing the Duty Medical Officer on 21 07 63 48.


Samples should be tested where there is suspicion of MERS-CoV. The recommended method is PCR.

The Department of Virology at the Norwegian Institute of Public Health (NIPH) has diagnostic tests for MERS-CoV and can receive samples from hospitalised patients for confirmation. The Department of Microbiology at St. Olav's Hospital in Trondheim can also perform diagnostic tests.

Two sets of respiratory samples for MERS test

Take samples from the upper and particularly the lower respiratory tract. Diagnostic experience with the first disease cases showed that virus detection is most successful with material from the lower respiratory tract. 

When the sample is taken, the NIPH recommends that two sets of respiratory specimens should be taken, e.g. from nasopharyngeal secretions and bronchial wash. Follow the hospital's infectious disease control procedures when taking samples. Consult the hospital's infectious disease control physician or Duty Medical Officer at the NIPH for isolation measures / infectious disease control measures and sampling. One set of samples should be analysed locally for common respiratory agents while the other should be sent to the Department of Virology at the NIPH for specific PCR analysis for MERS-CoV.

Co-infection is confirmed in some cases

Positive tests for other infections do not rule out infection with MERS-CoV, as co-infection (especially influenza) has been seen. Make arrangements in advance with the local microbiology laboratory and Department of Virology at the NIPH before shipment. 

When submitting the sample, include clinical information such as symptoms, their onset, date admitted to hospital, travel history and any underlying diseases in the notes. Mark clearly if there is MERS-CoV is suspected.

Transport of samples

Mix virus transport medium with the respiratory samples and transport under refrigeration at 4 °C (wet ice or cooling block that is not in direct contact with the sample). Label and pack the sample correctly. In practice it may be difficult for general practitioners and emergency rooms to send samples in a cooled state. In such cases, keep the sample cool until shipment. Transport should take place as quickly as possible to the local microbiology laboratory.

Repeated MERS tests?

Consider repeating respiratory tract tests if the first sample taken during the acute phase is negative, and there is still strong clinical suspicion. There have been reported cases where the initial test was negative and samples taken a few days later proved to be positive.

Other samples for MERS test

Faeces are also a relevant sample for direct virus detection, but testing of respiratory samples should take priority. Serum samples can also be taken for serological diagnosis that requires both acute phase samples and samples taken after 14-21 days. In cases of suspected coronavirus, patient information must be clearly marked with relevant information about the patient and the sample type.

Further information